HK1068501B - Pdgf-bb for the treatment of parkinson's disease - Google Patents
Pdgf-bb for the treatment of parkinson's disease Download PDFInfo
- Publication number
- HK1068501B HK1068501B HK05101145.7A HK05101145A HK1068501B HK 1068501 B HK1068501 B HK 1068501B HK 05101145 A HK05101145 A HK 05101145A HK 1068501 B HK1068501 B HK 1068501B
- Authority
- HK
- Hong Kong
- Prior art keywords
- cells
- pdgf
- vegf
- cell
- receptor
- Prior art date
Links
Claims (4)
- Humanes PDGF-BB zur Verwendung bei der Behandlung der Parkinson-Krankheit oder von Parkinson-Syndromen bei einem Patienten durch intraventrikuläre Infusion.
- Humanes PDGF-BB zur Verwendung nach Anspruch 1, in einer Menge von 0,1 ng/kg/Tag bis 1 µg/kg/Tag.
- Humanes PDGF-BB zur Verwendung nach Anspruch 1, in einer Menge von 0,5 ng/kg/Tag bis 500 ng/kg/Tag.
- Humanes PDGF-BB zur Verwendung nach Anspruch 1, wobei das Medikament die Differenzierung, Migration, Proliferation oder das Überleben von Nervenstammzellen oder Nervenvorläuferzellen in dem Patienten bewirkt.
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US32338101P | 2001-09-19 | 2001-09-19 | |
| US60/323,381 | 2001-09-19 | ||
| US32604401P | 2001-09-28 | 2001-09-28 | |
| US60/326,044 | 2001-09-28 | ||
| PCT/IB2002/003998 WO2003024478A1 (en) | 2001-09-19 | 2002-09-19 | Treatment of central nervous system disorders by use of pdgf or vegf |
Related Parent Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HK11108470.9A Division HK1154341A (en) | 2001-09-19 | 2005-02-12 | Pdgf for use in the treatment of central nervous system disorders |
| HK11106377.7A Division HK1152243B (en) | 2001-09-19 | 2005-02-12 | Vegf for use in the treatment of central nervous system disorders |
Related Child Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HK11108470.9A Addition HK1154341A (en) | 2001-09-19 | 2005-02-12 | Pdgf for use in the treatment of central nervous system disorders |
| HK11106377.7A Addition HK1152243B (en) | 2001-09-19 | 2005-02-12 | Vegf for use in the treatment of central nervous system disorders |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| HK1068501A1 HK1068501A1 (en) | 2005-04-22 |
| HK1068501B true HK1068501B (en) | 2013-05-31 |
Family
ID=
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1443955B1 (de) | Pdgf-bb zur behandlung von morbus parkinson | |
| AU2002334327A1 (en) | Treatment of central nervous system disorders by use of PDGF or VEGF | |
| US8318704B2 (en) | Modulation of neural stem cells and neural progenitor cells | |
| US20040038888A1 (en) | Functional role and potential therapeutic use of PACAP, VIP and Maxadilan in relation to adult neural stem or progenitor cells | |
| Prieto et al. | Gas6, a ligand for the receptor protein-tyrosine kinase Tyro-3, is widely expressed in the central nervous system | |
| US20030165485A1 (en) | Functional role and potential therapeutic use of Reelin, Gas6 and Protein S in relation to adult neural stem or progenitor cells | |
| Giacobini et al. | Hepatocyte growth factor acts as a motogen and guidance signal for gonadotropin hormone-releasing hormone-1 neuronal migration | |
| US20050003998A1 (en) | Therapeutic use of selective LXR modulators | |
| Bribian et al. | A novel role for anosmin‐1 in the adhesion and migration of oligodendrocyte precursors | |
| US20070149439A1 (en) | Pituitary adenylate cyclase-activating polypeptide (PACAP) is an anti-mitogenic signal for selected neuronal precursors in vivo | |
| AU2006203260B2 (en) | Treatment of Central Nervous System Disorders by Use of PDGF or VEGF | |
| US8481486B2 (en) | Methods of treating neurological diseases by regulating migration of neuroblasts in the adult nervous system with tenascin-R | |
| HK1068501B (en) | Pdgf-bb for the treatment of parkinson's disease | |
| HK1152243B (en) | Vegf for use in the treatment of central nervous system disorders | |
| HK1154341A (en) | Pdgf for use in the treatment of central nervous system disorders | |
| Williams | The cellular and molecular changes occurring in the degenerating and regenerating olfactory system | |
| EP1871407A2 (de) | Zusammensetzung mit wnt-3-peptid zur modulierung medial-lateraler nerventopographiekarten |